Insights

Gathering insights about DKI…

Similar companies to DKI

DKI Tech Stack

Media & News

Darkiris Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Hong Kong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games through various third-party digital storefronts, today announced that on November 18, 2025, it received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”). The Notice informed the Company that, based upon the closing bid price of the Company's Class A Ordinary Shares (“Shares”) over the 30 consecutive business day period between October 7, 2025 and November 17, 2025, the Company is not in compliance with the requirement to maintain a minimum bid price of $1.00 per share of its Shares for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company is issuing this press release in accordance with Nasdaq Listing Rule 5810(b) and instructions from the Notice.
Nov 21, 2025 | www.globenewswire.com
DarkIris Inc. Announces Closing of Initial Public Offering
Hong Kong, Aug. 11, 2025 (GLOBE NEWSWIRE) -- DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games through various third-party digital storefronts, today announced the closing of its initial public offering (the “Offering”) of 1,725,000 Class A ordinary shares (which includes full exercise of the underwriters' over-allotment option) at a public offering price of US$4.00 per Class A ordinary share. The Class A ordinary shares began trading on the Nasdaq Capital Market on August 8, 2025 under the ticker symbol “DKI.
Aug 11, 2025 | www.globenewswire.com

DKI's Email Address Formats

DKI uses at least 1 format(s):

DKI Email Formats	Example	Percentage
FLast@dkidirect.com	JDoe@dkidirect.com	49%
First@dkidirect.com	John@dkidirect.com	1%
FLast@dkidirect.com	JDoe@dkidirect.com	49%
First@dkidirect.com	John@dkidirect.com	1%

Frequently Asked Questions

Where is DKI's headquarters located?

DKI's main headquarters is located at 155 Passaic Avenue, Fairfield, NJ 07004, US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is DKI's phone number?

You can contact DKI's main corporate office by phone at

+1-818-352-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is DKI's stock symbol?

DKI is a publicly traded company; the company's stock symbol is DKI.

What is DKI's official website and social media links?

DKI's official website is dkidirect.com and has social profiles on LinkedIn.

What is DKI's SIC code NAICS code?

DKI's SIC code is 8742 - Management Consulting Services NAICS code is 541613 - Marketing Consulting Services.

How many employees does DKI have currently?

As of October 2025, DKI has approximately 213 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Owner: D. K.Co-Owner: C. P.Project Manager: B. H.. Explore DKI's employee directory with LeadIQ.

What industry does DKI belong to?

DKI operates in the Advertising Services industry.

What is DKI's email format?

DKI's email format typically follows the pattern of FLast@dkidirect.com. Find more DKI email formats with LeadIQ.

DKI

Advertising ServicesUnited States201-500 Employees

DKI is a full-service healthcare relationship marketing (RM) agency. With industry-leading experience in the digital world—coupled with a distinctive ROI-based model—we consistently provide outstanding client service, innovation, and positive program results. Our base of core values defines the way we work, with our clients and each other.

For nearly 15 years, our expertise has been interactive RM programs for patients, caregivers, and healthcare professionals, with a focus on oncology, specialty, and orphan drugs. What makes us unique in each of these areas is our ability to understand the mindset of our audiences and provide relevant content  that reaches highly dispersed targets.